Table 2.
Randomized controlled trials of CS in paediatric patients with ARDS.
| Author (Year) | Diagnosis | Total No. of Patients (CS/Placebo) |
Treatment/Dose | Duration of Treatment (Days) | Outcomes in CS Groups |
|---|---|---|---|---|---|
| Drago et al. (2015) [107] | Paediatric ARDS | 35 (17 CS, 18 placebo) |
Methylprednisolone (loading dose 2 mg/kg, then 1 mg/kg/day infusion) |
7 | No differences in length of mechanical ventilation, ICU stay, hospital stay, or mortality Lower PaCO2 on days 2 and 3, higher pH on day 2, and higher PaO2/FiO2 on days 8 and 9 Lower requirement for treatment of postextubation stridor or supplemental oxygen at ICU transfer No adverse effects |
| Schwingshackl et al. (2016) [108] | Paediatric ARDS | 35 (17 CS, 18 placebo) |
Methylprednisolone (loading dose 2 mg/kg, then 1 mg/kg/day infusion) |
7 | On day 7, increased WBC and platelets counts, lower IFN-α, IL-6, IL-10, MCP-1, G-CSF and GM-CSF levels, and higher IL-17α levels in comparison to study entry |
| Kimura et al. (2016) [109] | Paediatric ARDS | 35 (17 CS, 18 placebo) |
Methylprednisolone (loading dose 2 mg/kg, then 1 mg/kg/day infusion) |
7 | On day 7, reduction in MMP-8 levels, no increases in sICAM-1, on day 8 positive correlation of sRAGE levels with PaO2/FiO2, negative correlation of O2 requirements at ICU transfer with day 7 sICAM-1 levels |